NICE appraisal of bortezomib for the treatment of relapsed and refractory multiple myeloma
The National Institute for Health and Clinical Excellence (NICE) is currently appraising the use of bortezomib (Velcade) for the treatment of multiple myeloma as part of its rapid appraisal work programme. Following reports in two national newspapers on the content of draft guidance on this drug, due for publication next week, NICE has decided to publish the draft guidance on its website with immediate effect.
Further information
 |
NICE appraisal of bortezomib for the treatment of relapsed and refractory multiple myeloma 20 October 2006 (36.4Kb 13sec @ 28.8Kbps) |
This page was last updated: 10 September 2009
